



Correction to: Fuzuloparib: First Approval

Arnold Lee¹

Published online: 10 July 2021
© Springer Nature Switzerland AG 2021

Correction to: Drugs

<https://doi.org/10.1007/s40265-021-01541-x>

Since publication online on 12 June 2021 of this AdisInsight Report on Fuzuloparib (AiRuiYi[®], 艾瑞颐; formerly fluzoparib), the agent was approved in China for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy on 22nd June 2021 [1].

Reference

1. NMPA approval website https://mp.weixin.qq.com/s/uJ0hgF_72eAzNLNUGfSuPQ. Accessed 2 July 2021.

The original article can be found online at <https://doi.org/10.1007/s40265-021-01541-x>.

✉ Arnold Lee
dru@adis.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand